BioCryst Pharmaceuticals Inc (BCRX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, BioCryst Pharmaceuticals Inc (BCRX) has a cash flow conversion efficiency ratio of 0.112x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-62.14 Million) by net assets ($-553.84 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see BioCryst Pharmaceuticals Inc market cap and net worth for the company's overall valuation and market capitalisation.
BioCryst Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (1994–2025)
This chart illustrates how BioCryst Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
BioCryst Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BioCryst Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Explore BCRX cash to earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
HUISHANG BK CORP. H YC1
F:HB8
|
N/A |
|
BHP Group Limited
LSE:BHP
|
0.205x |
|
Parex Resources Inc
TO:PXT
|
0.082x |
|
Aker Solutions ASA
OL:AKSO
|
0.124x |
|
Youngone
KO:111770
|
-0.018x |
|
Kodiak Sciences Inc
NASDAQ:KOD
|
-0.757x |
|
Via Transportation, Inc.
NASDAQ:VIA
|
-0.017x |
|
Extreme Networks Inc
NASDAQ:EXTR
|
0.523x |
Annual Cash Flow Conversion Efficiency for BioCryst Pharmaceuticals Inc (1994–2025)
The table below shows the annual cash flow conversion efficiency of BioCryst Pharmaceuticals Inc from 1994 to 2025. View BCRX stock price and chart for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-119.15 Million | $329.88 Million | -2.769x | -2632.95% |
| 2024-12-31 | $-475.93 Million | $-52.02 Million | 0.109x | -47.67% |
| 2023-12-31 | $-455.53 Million | $-95.14 Million | 0.209x | -61.98% |
| 2022-12-31 | $-294.60 Million | $-161.85 Million | 0.549x | -58.65% |
| 2021-12-31 | $-106.99 Million | $-142.16 Million | 1.329x | -81.35% |
| 2020-12-31 | $-19.26 Million | $-137.22 Million | 7.124x | +404.18% |
| 2019-12-31 | $38.25 Million | $-89.58 Million | -2.342x | -24.57% |
| 2018-12-31 | $49.23 Million | $-92.56 Million | -1.880x | -282.78% |
| 2017-12-31 | $83.77 Million | $-41.14 Million | -0.491x | +98.55% |
| 2016-12-31 | $1.58 Million | $-53.44 Million | -33.864x | -12221.93% |
| 2015-12-31 | $47.72 Million | $-13.12 Million | -0.275x | +46.08% |
| 2014-12-31 | $75.64 Million | $-38.55 Million | -0.510x | -102.16% |
| 2013-12-31 | $-1.13 Million | $-26.53 Million | 23.561x | -71.40% |
| 2012-12-31 | $-454.00K | $-37.40 Million | 82.372x | +3881.60% |
| 2011-12-31 | $14.81 Million | $-32.25 Million | -2.178x | -408.23% |
| 2010-12-31 | $66.62 Million | $-28.55 Million | -0.429x | -127.97% |
| 2009-12-31 | $86.27 Million | $-16.22 Million | -0.188x | +58.19% |
| 2008-12-31 | $46.43 Million | $-20.87 Million | -0.450x | -16.74% |
| 2007-12-31 | $64.91 Million | $-25.00 Million | -0.385x | +46.44% |
| 2006-12-31 | $21.16 Million | $-15.21 Million | -0.719x | -79.99% |
| 2005-12-31 | $58.44 Million | $-23.35 Million | -0.399x | +35.44% |
| 2004-12-31 | $29.33 Million | $-18.15 Million | -0.619x | -57.22% |
| 2003-12-31 | $28.45 Million | $-11.20 Million | -0.394x | +3.49% |
| 2002-12-31 | $40.13 Million | $-16.36 Million | -0.408x | -128.07% |
| 2001-12-31 | $56.81 Million | $-10.16 Million | -0.179x | -245.95% |
| 2000-12-31 | $61.48 Million | $-3.18 Million | -0.052x | +24.69% |
| 1999-12-31 | $71.40 Million | $-4.90 Million | -0.069x | +54.74% |
| 1998-12-31 | $27.70 Million | $-4.20 Million | -0.152x | +62.76% |
| 1997-12-31 | $25.30 Million | $-10.30 Million | -0.407x | -111.94% |
| 1996-12-31 | $35.40 Million | $-6.80 Million | -0.192x | +71.81% |
| 1995-12-31 | $11.30 Million | $-7.70 Million | -0.681x | -17.41% |
| 1994-12-31 | $11.20 Million | $-6.50 Million | -0.580x | -- |
About BioCryst Pharmaceuticals Inc
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to… Read more